Woodruff: Clinical Research Should Be More Gender-Specific



By Deborah Borfitz

June 16, 2008 | In virtually every medical discipline, there are unanswered questions pertaining to women’s health and well-being. Closing the gender gap in medical research may require more than simply including women in research studies, says Teresa Woodruff, executive director of the Institute for Women’s Health Research, recently launched by Northwestern University’s Feinberg School of Medicine.

“Women experience disease symptoms and respond to therapeutic treatments differently throughout their lifespan and across their monthly menstrual cycle,” says Woodruff. Hormone fluctuations and the possibility of pregnancy among pre-menopausal women have for decades been the rationale for excluding females from medical research. To this day, many researchers prefer using male animals over female animals in their laboratories simply because their hormone environment is less complicated.

 Teresa Woodruff,  Institute for Women's Health, Northwestern University 
Teresa Woodruff
Since the early 1990s, women have been represented as study subjects in higher numbers because the National Institutes of Health, as a condition of funding, now requires that researchers include women in all studies targeting diseases that impact both sexes. However, when male and female trial data gets blended, sex- and gender-specific findings are difficult to evaluate unless the trial was specifically designed to look for sexual dimorphisms, says Woodruff.

Traditionally, women’s health research has focused on issues such as pregnancy, menopause, and female-specific cancers, she adds. Only in the last five years, for example, has the medical community identified sex differences in cardiovascular disease, the leading killer of both men and women. Even far less is known about diagnosing and treating women with diseases of the brain, the musculoskeletal organs, and the immune system. Most reports on adverse drug reactions occur in women because females were not included in many of the early pharmaceutical studies.

Woodruff believes that women want to be a part of the answer. The Institute’s latest project, the Illinois Women’s Health Registry, opened three months ago and has already enrolled over 1,000 Illinois women who are willing to take part in Institutional Review Board-approved research conducted at Northwestern University. Registry participants will be matched to specific studies based on their self-reported health profiles. Woodruff says she hopes the registry “will help us identify priorities that will raise the health status of Illinois women, who now rank 33rd among the states.”

In addition to the registry, the Institute for Women’s Health Research is facilitating more women’s research by offering seed grants to young investigators and by developing an Animal Research Core that will encourage researchers to use female animal models in their studies.

“More physicians are beginning to recognize that sex and gender impact health, but they do not necessarily know the way it relates to age or genetics,” says Woodruff. “That level of sophistication doesn’t exist yet.” But “before we can get to personalized medicine, we need to understand basic sex differences.”

Woodruff predicts, “Ten years from now, the treatment of women and men will be different than it is today because of programs like the Institute for Women’s Health Research.”

________________________________

 This story first appeared in eCliniqua,one of Bio-IT World’s free e-newsletters. Subscribe here.

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .